Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | NT5E | P21589 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.55 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.55 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | SNCA | P37840 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6238272 | 1.00 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2KMT2ANT5E | |
| SCHEMBL16316028 | 0.91 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2KMT2ALMNA | |
| SCHEMBL9767723 | 0.87 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2KMT2ANT5E | |
| SCHEMBL10939703 | 0.87 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2KMT2ANT5E | |
| SCHEMBL611657 | 0.87 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2KMT2ANT5E | |
| SCHEMBL9823741 | 0.85 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2KMT2ANT5E | |
| SCHEMBL9823737 | 0.85 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2KMT2ANT5E | |
| SCHEMBL22946413 | 0.85 | HSD11B1 (0.49) | RAB9AKMT2AMAPK1MAPTMEN1 | |
| SCHEMBL15652067 | 0.84 | ALDH1A1 (0.68) | NPC1RAB9AKMT2ALMNAMEN1 | |
| SCHEMBL11772637 | 0.84 | ALDH1A1 (0.68) | NPC1RAB9AKMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116464-B | (E) -4- (pyridylformylhydrazono) -N-phenylbenzamide antitumor compounds | 中国医科大学 | 2022-09-13 | — | — | CN | disclosed |
| CN-111116464-A | (E) -4- (pyridylformylhydrazono) -N-phenylbenzamide antitumor compounds | 中国医科大学 | 2020-05-08 | — | — | CN | disclosed |
| EP-1284267-B1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | SANKYO CO (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-6653330-B2 | Such as 4'-chloro-4-(5-(3-(2,4-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4 -triazol-1-y)butyl)-1,3-dioxan-2-yl)-benzanilide; antifungal activity | SANKYO COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | SANKYO COMPANY, LIMITED (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1284267-A1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | Sankyo Company, Limited (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | NAT1, ERG28, DPM1 | NPC1 361/4885RAB9A 1988/4885SMN1; SMN2 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.